Oncology
Lymphoma, T Cell, Peripheral
2
Pipeline Programs↗
0
Active Trials↗
2
Companies Involved↗
Lymphoma, T Cell, Peripheral is an early-stage landscape with 2 programs across 2 companies. The most active players are Karuna Therapeutics, Inc., a Bristol Myers Squibb company, Bristol-Myers Squibb.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 12
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
2programs
Small molecule150%
Protein / enzyme150%
Modality classified for 100% of 2 pipeline programs.
Analysis
Trial Status
1
clinical trials
Suspended1 · 100%
Clinical Trials
Trial Activity
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)